BillionToOne, founded with a mission to make molecular diagnostics more accurate and accessible, leverages its proprietary DNA molecular counter technology to enhance the resolution of cell-free DNA diagnostics by over 1,000 fold. The company's flagship product, Unity Screen, is a non-invasive prenatal test (NIPT) that uniquely assesses fetal risk for both recessive conditions and aneuploidies from maternal blood. BillionToOne focuses on transformative improvements in prenatal screening and liquid biopsy for cancers, aiming to revolutionize these markets with its innovative solutions.

Notable figures affiliated with BillionToOne include its leadership team and board members who bring extensive expertise in genetics and biotechnology. The company has attracted significant investment from prominent venture capital firms, fueling its rapid growth and development. Key achievements include the exponential adoption of Unity Screen in the prenatal testing market and the ongoing advancements in their oncology diagnostics. BillionToOne's impact lies in its ability to provide more precise and comprehensive genetic testing, ultimately improving patient outcomes and advancing the field of molecular diagnostics.